Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

China · Delayed Price · Currency is CNY

13.68

+0.44 (3.32%)

Jun 29, 2026, 3:00 PM CST

-12.76% (1Y)

Market Cap	20.44B -16.2%
Revenue (ttm)	8.35B -1.9%
Net Income	1.16B +19.1%
EPS	0.78 +19.1%
Shares Out	1.49B
PE Ratio	17.61
Forward PE	11.90
Dividend	0.31 (2.34%)
Ex-Dividend Date	May 29, 2026

Volume	14,986,296
Open	13.18
Previous Close	13.24
Day's Range	12.90 - 13.73
52-Week Range	12.90 - 17.69
Beta	0.31
Analysts	Buy
Price Target	17.18 (+25.59%)
Earnings Date	Aug 14, 2026

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical drugs. It also engages in medical instruments, agriculture, and chain drugstore activities. The company was formerly known as Tianjin Tasly Pharmaceut... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1994

Employees 10,563

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600535

Full Company Profile

Financial Performance

In 2025, SHA:600535's revenue was 8.24 billion, a decrease of -3.08% compared to the previous year's 8.50 billion. Earnings were 1.10 billion, an increase of 15.63%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for 600535 stock is "Buy." The 12-month stock price target is ¥17.18, which is an increase of 25.59% from the latest price.

Price Target

¥17.18

(25.59% upside)

Analyst Consensus: Buy

Stock Forecasts